Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
Zilebesiran demonstrated an encouraging safety and tolerability profile when added to these standard of care antihypertensives.
- Zilebesiran demonstrated an encouraging safety and tolerability profile when added to these standard of care antihypertensives.
- “We are thrilled that a single dose of zilebesiran achieved clinically significant, additional reductions in systolic blood pressure when administered to patients who are not adequately controlled with commonly prescribed antihypertensives,” said Simon Fox, Ph.D., Vice President, Zilebesiran Program Lead at Alnylam.
- “These KARDIA-2 results, showing durable additional levels of blood pressure reduction on top of what is achieved by standard of care first-line antihypertensives with an encouraging safety profile, reinforce our confidence in zilebesiran’s differentiated profile.
- The primary endpoint is the change from baseline in mean SBP at Month 3, assessed by 24-hour ABPM.